
KISQALI is a prescription medicine used in combination with a certain type of medicine as the first hormonal based therapy to treat women who have gone through menopause with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic).
It is not known if KISQALI is safe and effective in children.
Your healthcare provider may tell you to decrease your dose, temporarily stop or completely stop taking KISQALI if you develop certain serious side effects during treatment with KISQALI.

Ask your healthcare provider if you do not know.
Before you take KISQALI, tell your healthcare provider if you:
Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. KISQALI and other medicines may affect each other causing side effects.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use KISQALI for a condition for which it was not prescribed. Do not give KISQALI to other people, even if they have the same symptoms you have. It may harm them.
Active ingredient: Ribociclib
Inactive ingredient: Colloidal silicon dioxide, crospovidone, hydroxypropylcellulose, magnesium stearate and
microcrystalline cellulose. The film-coating contains iron oxide black, iron oxide red, lecithin (soya), polyvinyl alcohol
(partially hydrolyzed), talc, titanium dioxide, and xanthan gum